Mainz Biomed Unveils Industry-Leading Study Results at ASCO 2024

Mainz Biomed N.V. has released promising results from a pooled study presented at the ASCO 2024 Annual Meeting in Chicago. The study, which includes data from the ColoFuture and eAArly DETECT studies, confirmed high sensitivity rates for detecting colorectal cancer (CRC) and advanced adenomas. Specifically, the sensitivity for CRC was 92.3%, while high-grade dysplasia detection reached 95.8%.

This large-scale analysis involved 690 clinical subjects from 30 gastroenterology centers across Europe and the United States. The multimodal screening test used integrates the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, supported by advanced AI algorithms. This combination enhances the differentiation between CRC, advanced adenomas, non-advanced adenomas, and samples with no pathological findings.

Dr. Kim Turgeon emphasized the potential of this non-invasive test to improve early detection and prevention of CRC. Dr. Moritz Eidens highlighted the robust efficacy of the multimodal approach, significantly improving the accuracy of CRC and advanced adenoma detection compared to current non-invasive tests.